<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-08-14">14 August 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Christina</forename><surname>Charles-Schoeman</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerd</forename><surname>Burmester</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Charité-University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Nash</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Rheumatology Research Unit</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Nambour Hospital, Sunshine Coast</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of Queensland</orgName>
								<address>
									<settlement>Queensland</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cristiano</forename><forename type="middle">A F</forename><surname>Zerbini</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Centro Paulista de Investigação Clinica</orgName>
								<address>
									<settlement>São Paulo</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Koshika</forename><surname>Soma</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Pfizer Inc</orgName>
								<address>
									<settlement>Groton</settlement>
									<region>Connecticut</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kenneth</forename><surname>Kwok</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Pfizer Inc</orgName>
								<address>
									<settlement>New York</settlement>
									<region>New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thijs</forename><surname>Hendrikx</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Pfizer Inc</orgName>
								<address>
									<settlement>Collegeville</settlement>
									<region>Pennsylvania</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Eustratios</forename><surname>Bananis</surname></persName>
							<email>stratis.bananis@pfizer.com</email>
							<affiliation key="aff8">
								<orgName type="institution">Pfizer Inc</orgName>
								<address>
									<settlement>Collegeville</settlement>
									<region>Pennsylvania</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roy</forename><surname>Fleischmann</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Metroplex Clinical Research Center</orgName>
								<orgName type="institution">University of Texas Southwestern Medical Center</orgName>
								<address>
									<settlement>Dallas</settlement>
									<region>Texas</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Inflammation &amp; Immunology</orgName>
								<orgName type="department" key="dep2">Global Innovative Pharma</orgName>
								<orgName type="institution" key="instit1">US Medical Affairs</orgName>
								<orgName type="institution" key="instit2">Pfizer Inc</orgName>
								<address>
									<addrLine>500 Arcola Road</addrLine>
									<postCode>19426</postCode>
									<settlement>Collegeville</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-08-14">14 August 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">709A44551A9F994B460A82584BFECF02</idno>
					<idno type="DOI">10.1136/annrheumdis-2014-207178</idno>
					<note type="submission">Received 18 December 2014 Revised 24 June 2015 Accepted 14 July 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:29+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Trial registration numbers (NCT00413660</term>
					<term>NCT0050446</term>
					<term>NCT00603512</term>
					<term>NCT00687193</term>
					<term>NCT00960440</term>
					<term>NCT00847613</term>
					<term>NCT00814307</term>
					<term>NCT00856544</term>
					<term>NCT00853385)</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives Biological disease-modifying antirheumatic drugs (bDMARDs) have shown diminished clinical response following an inadequate response (IR) to ≥1 previous bDMARD.</s><s>Here, tofacitinib was compared with placebo in patients with an IR to conventional synthetic DMARDs (csDMARDs; bDMARD-naive) and in patients with an IR to bDMARDs (bDMARD-IR).</s><s>Methods Data were taken from phase II and phase III studies of tofacitinib in patients with rheumatoid arthritis (RA).</s><s>Patients received tofacitinib 5 or 10 mg twice daily, or placebo, as monotherapy or with background methotrexate or other csDMARDs.</s><s>Efficacy endpoints and incidence rates of adverse events (AEs) of special interest were assessed.</s><s>Results 2812 bDMARD-naive and 705 bDMARD-IR patients were analysed.</s><s>Baseline demographics and disease characteristics were generally similar between treatment groups within subpopulations.</s><s>Across subpopulations, improvements in efficacy parameters at month 3 were generally significantly greater for both tofacitinib doses versus placebo.</s><s>Clinical response was numerically greater with bDMARD-naive versus bDMARD-IR patients (overlapping 95% CIs).</s><s>Rates of safety events of special interest were generally similar between tofacitinib doses and subpopulations; however, patients receiving glucocorticoids had more serious AEs, discontinuations due to AEs, serious infection events and herpes zoster.</s><s>Numerically greater clinical responses and incidence rates of AEs of special interest were generally reported for tofacitinib 10 mg twice daily versus tofacitinib 5 mg twice daily (overlapping 95% CIs).</s><s>Conclusions Tofacitinib demonstrated efficacy in both bDMARD-naive and bDMARD-IR patients with RA.</s><s>Clinical response to tofacitinib was generally numerically greater in bDMARD-naive than bDMARD-IR patients.</s><s>The safety profile appeared similar between subpopulations.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>1]<ref type="bibr" target="#b14">[12]</ref><ref type="bibr" target="#b15">[13]</ref><ref type="bibr" target="#b16">[14]</ref><ref type="bibr" target="#b17">[15]</ref><ref type="bibr" target="#b18">[16]</ref><ref type="bibr" target="#b19">[17]</ref><ref type="bibr" target="#b20">[18]</ref><ref type="bibr" target="#b21">[19]</ref><ref type="bibr" target="#b22">[20]</ref><ref type="bibr" target="#b23">[21]</ref> It is important that new RA therapies demonstrate efficacy and tolerability in RA patient populations with varying disease duration and prior treatment exposure to reflect the variability seen in clinical practice.</s></p><p><s>Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.</s><s>The clinical efficacy and safety of tofacitinib 5 and 10 mg twice daily as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) for the treatment of RA has been reported previously in phase II, <ref type="bibr" target="#b25">[22]</ref><ref type="bibr" target="#b26">[23]</ref><ref type="bibr" target="#b27">[24]</ref><ref type="bibr" target="#b28">[25]</ref><ref type="bibr" target="#b29">[26]</ref> phase III <ref type="bibr" target="#b33">[27]</ref><ref type="bibr" target="#b34">[28]</ref><ref type="bibr" target="#b35">[29]</ref><ref type="bibr" target="#b36">[30]</ref><ref type="bibr" target="#b37">[31]</ref><ref type="bibr" target="#b38">[32]</ref> and long-term extension (LTE) clinical studies. <ref type="bibr" target="#b39">33</ref></s><s>atients receiving tofacitinib in the RA development programme included those who were naive to or had an IR to bDMARDs.</s><s>The objectives of these analyses were to compare the efficacy and safety of tofacitinib 5 and 10 mg twice daily versus placebo in patients who had an IR to csDMARDs only (bDMARD-naive), and patients with an IR to previous bDMARDs including tumour necrosis factor inhibitors (TNFi; bDMARD-IR).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical studies Phase II studies</head><p><s>The four phase II studies were randomised, doubleblind, placebo-controlled studies: A3921025 (NCT00413660), A3921035 (NCT00550446), A3921039 (NCT00603512) and A3921040 (NCT00687193).</s><s>Patients received tofacitinib 1, 3, 5, 10 or 15 mg twice daily, tofacitinib 20 mg once daily (A3921025) or placebo, as monotherapy (A3921035 and A3921040) or in combination with background methotrexate (A3921025 and A3921039).</s><s>A3921035 included a monotherapy adalimumab arm.</s><s>Patients had an IR to a bDMARD or csDMARD (A3921035 and A3921040), or methotrexate (A3921025 and A3921039).</s><s>5]<ref type="bibr" target="#b29">[26]</ref> Phase III studies</s></p><p><s>The five phase III studies were double-blind, placebo-controlled, global studies: ORAL Step (A3921032; NCT00960440), ORAL Scan (A3921044; NCT00847613), ORAL Solo (A3921045; NCT00814307), ORAL Sync (A3921046; NCT00856544) and ORAL Standard (A3921064; NCT00853385).</s><s>Patients had an IR to a bDMARD or csDMARD (ORAL Solo and ORAL Sync), methotrexate (ORAL Scan and ORAL Standard) or TNFi (ORAL Step).</s><s>Patients with RA received tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily or placebo, as monotherapy (ORAL Solo), with background csDMARDs (ORAL Sync) or with background methotrexate (ORAL Standard, ORAL Scan, ORAL Step).</s><s>ORAL Standard included an adalimumab plus methotrexate arm.</s><s>In ORAL Sync, ORAL Standard and ORAL Scan, placebo patients who did not achieve ≥20% decrease in tender/swollen joints were treated with tofacitinib at month 3.</s><s>All remaining placebo patients were treated with tofacitinib at month 6.</s><s>8]<ref type="bibr" target="#b35">[29]</ref><ref type="bibr" target="#b36">[30]</ref><ref type="bibr" target="#b37">[31]</ref> After the publication of ORAL Standard, one of its study sites (nine patients randomised) was found to be non-compliant to study procedures and those patients have been removed from the efficacy analyses presented here.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient subpopulations</head><p><s>IR was defined as discontinuation due to lack of efficacy, an adverse event (AE), or both, in all studies except for study A3921039, which did not collect the same detailed information.</s></p><p><s>Two analysis cohorts were included: pooled phase II and phase III studies (P2/P3) cohort, and the pooled phase III studies (P3) cohort.</s><s>The P2/P3 cohort included patients from the four phase II and five phase III studies.</s><s>The P3 cohort included patients from the five phase III studies.</s></p><p><s>The following patient subpopulations were analysed in both P2/P3 and P3 cohorts according to prior DMARD experience and response to DMARD therapy: ▸ bDMARD-naive: patients who had an IR to csDMARDs only ▸ bDMARD-IR: patients with an IR to previous TNFi or other bDMARDs.</s></p><p><s>For the P2/P3 cohort, the following patient subpopulations were analysed according to previous TNFi exposure: ▸ bDMARD-naive: patients who had an IR to csDMARDs only ▸ patients who were IR to one previous TNFi ▸ patients who were IR to multiple previous TNFi (≥2 previous TNFi).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy and safety analyses</head><p><s>The following efficacy parameters were assessed: American College of Rheumatology (ACR) 20/50/70 response rates; disease activity score (DAS)28-4(erythrocyte sedimentation rate) (ESR); Health Assessment Questionnaire-Disability Index (HAQ-DI); Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI).</s><s>Efficacy comparisons were performed on the P2/P3 cohort at months 3 and 6.</s><s>Safety parameters assessed using exposure estimates and incidence rates ( patients with event per 100 patient-years of observation) included discontinuations due to AEs; serious AEs (SAEs); all-cause mortality; malignancies (excluding nonmelanoma skin cancer (NMSC)); lymphoma/lymphoproliferative disorders; all herpes zoster (HZ; serious and non-serious); serious HZ; serious infection events (SIEs); tuberculosis (TB); opportunistic infections (excluding TB) and major adverse cardiovascular events.</s><s>Safety was assessed in the P3 cohort during months 0-6 for placebo and months 0-24 for tofacitinib.</s><s>Patients initially treated with placebo were counted in the placebo group until treatment with tofacitinib.</s><s>Safety endpoints were analysed in the P3 cohort only and not the P2/P3 cohort due to the phase II studies containing multiple doses and titrations of tofacitinib, thereby making it difficult to assign a safety event to a specific tofacitinib 5 or 10 mg twice daily dose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>All efficacy and safety analyses were based on the full analyses set-all patients who were randomised and received ≥1 dose of study treatment (tofacitinib or placebo).</s></p><p><s>For binary efficacy variables, missing values were computed using non-responder imputation, except for CDAI and SDAI (low-disease activity or remission) where observed case data were used.</s><s>Testing for treatment differences between tofacitinib and placebo was based on the normal approximation.</s><s>For continuous variables, missing values were handled by the linear mixed-effect models (used to assess the treatment effects).</s><s>For the exploratory analysis of tofacitinib versus placebo at month 3, statistical significance was declared at p&lt;0.05, without multiplicity corrections to preserve type I error.</s></p><p><s>The 95% CIs were presented for the bDMARD-naive and bDMARD-IR subpopulations.</s><s>For binary efficacy variables, exact binomial intervals were calculated, and for continuous efficacy variables, normal approximation was used.</s></p><p><s>All safety analyses were based on observed cases.</s><s>Incidence rates for safety parameters were calculated by exposure and dose.</s><s>Incidence rates were based on the number of patients with an event and total exposure time censored at time of event, death or withdrawal from the study; 95% CIs for incidence rates were based on maximum likelihood estimation.</s><s>A subanalysis of incidence rates for safety events of special interest for patients with/without concomitant glucocorticoid treatment was also performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS Patients</head><p><s>A total of 1071, 1090 and 651 bDMARD-naive patients were randomised to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and placebo, respectively.</s><s>In the bDMARD-IR subpopulation, 259, 253 and 193 patients were randomised to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and placebo, respectively.</s><s>In the bDMARD-IR group, discontinuations of prior bDMARDs occurred due to lack of efficacy (68.4%),</s><s>AEs (7.2%) and both lack of efficacy and AEs (24.4%).</s></p><p><s>Baseline demographics and disease characteristics were generally similar for tofacitinib versus placebo groups (table <ref type="table" target="#tab_0">1</ref>).</s><s>Compared with bDMARD-naive patients, a higher proportion of bDMARD-IR patients were Caucasian, had a higher mean body mass index, were from the USA, had longer mean disease duration and slightly greater mean disease activity at baseline (table <ref type="table" target="#tab_0">1</ref>).</s><s>Compared with bDMARD-IR patients, higher proportions of bDMARD-naive patients were from Latin America or rest of world, had previously taken csDMARDs other than methotrexate and were rheumatoid factor positive (table 1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Tofacitinib 5 mg twice daily Tofacitinib 5 mg twice daily versus placebo</head><p><s>In both bDMARD-naive and bDMARD-IR patients, a significantly ( p&lt;0.05) greater proportion of patients in the tofacitinib 5 mg twice daily group versus placebo achieved ACR20/50/70 response rates at month 3 (figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Furthermore, least-squares mean changes from baseline at month 3 in HAQ-DI and DAS28-4(ESR) (figure <ref type="figure" target="#fig_1">2</ref>), and improvements in other efficacy parameters, were significantly ( p&lt;0.05) higher for tofacitinib 5 mg twice daily versus placebo, except the percentage of patients achieving improvements ≥0.22 in HAQ-DI for bDMARD-IR patients (table <ref type="table" target="#tab_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tofacitinib 5 mg twice daily versus placebo by prior TNFi exposure</head><p><s>For the bDMARD-naive subpopulation, improvements were significantly ( p&lt;0.05) greater for tofacitinib 5 mg twice daily versus placebo across all efficacy endpoints at month 3 (see online supplementary table <ref type="table" target="#tab_0">S1</ref>).</s><s>In the 1 and ≥2 previous TNFi groups, tofacitinib 5 mg twice daily resulted in significant ( p&lt;0.05) improvements versus placebo in efficacy endpoints at month 3, except DAS28-4(ESR)≤3.2</s><s>and &lt;2.6, and HAQ-DI ≤0.5 for one previous TNFi, and ACR70, CDAI≤10 and ≤2.8, HAQ-DI≤0.5 and SDAI≤11 for ≥2 previous TNFi, although all responses were numerically higher for tofacitinib versus placebo (see online supplementary table <ref type="table" target="#tab_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tofacitinib 5 mg twice daily bDMARD-naive versus bDMARD-IR analyses</head><p><s>At months 3 and 6, improvements in clinical responses were numerically greater for bDMARD-naive versus bDMARD-IR patients, except SDAI≤3.3 at month 3 and DAS28-4(ESR)≤3.2 at month 6; 95% CIs were overlapping for most efficacy parameters, except ACR20 at month 3 (figure <ref type="figure" target="#fig_0">1</ref>; tables 2 and 3).</s><s>At month 3, improvements in clinical responses were numerically greater for bDMARD-naive patients versus one previous TNFi patient versus ≥2 previous TNFi patients for tofacitinib 5 mg twice daily, except CDAI and SDAI remission endpoints; 95% CIs were overlapping for most efficacy parameters, except ACR20 (see online supplementary table <ref type="table" target="#tab_0">S1</ref>).</s><s>In both bDMARD-naive and bDMARD-IR patients, improvements in all efficacy parameters were significantly ( p&lt;0.05) greater for tofacitinib 10 mg twice daily versus placebo (figures 1 and 2 and table 2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tofacitinib 10 mg twice daily versus placebo by prior TNFi exposure</head><p><s>For the bDMARD-naive, and 1 and ≥2 previous TNFi groups, improvements were significantly ( p&lt;0.05) greater for tofacitinib 10 mg twice daily versus placebo across all efficacy endpoints at month 3, except ACR70, CDAI≤10 and ≤2.8, and DAS28-4 (ESR)&lt;2.6 for ≥2 previous TNFi, although all responses were numerically higher for tofacitinib versus placebo (see online supplementary table <ref type="table" target="#tab_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tofacitinib 10 mg twice daily bDMARD-naive versus bDMARD-IR analyses</head><p><s>At months 3 and 6, improvements in clinical responses were numerically greater for bDMARD-naive versus bDMARD-IR patients, except DAS28-4(ESR)&lt;2.6 at month 6; 95% CIs were overlapping for most efficacy parameters, except ACR20 at month 3 (figures 1 and 2; tables 2 and 3).</s></p><p><s>Improvements in clinical responses at month 3 were numerically greater for all efficacy parameters for bDMARD-naive patients versus one previous TNFi patient versus ≥2 previous TNFi patients with the following exceptions: SDAI&lt;11 and LS mean change from baseline in HAQ-DI (in bDMARD-naive and one previous TNFi group); LS mean change from baseline in DAS28-4(ESR) (in bDMARD-naive and ≥2 previous TNFi groups) ACR20 (in one previous TNFi and ≥2 previous TNFi groups); 95% CIs were overlapping for most efficacy parameters, except ACR20 (see online supplementary table <ref type="table" target="#tab_0">S1</ref>).</s></p><p><s>Safety: tofacitinib 5 mg twice daily and tofacitinib 10 mg twice daily Incidence rates were numerically higher for both tofacitinib doses versus placebo for SIEs, HZ and malignancies (excluding NMSC); bDMARD-IR versus bDMARD-naive subpopulations for discontinuations due to AEs, HZ and malignancies (excluding NMSC) (table <ref type="table" target="#tab_3">4</ref>).</s><s>Despite the noted numerical differences, 95% CIs were generally overlapping when comparing each tofacitinib dose versus placebo within each subpopulation.</s><s>The CIs of incidence rates for safety events in the placebo and bDMARD-IR groups were wider versus the bDMARD-naive tofacitinib groups due to the lower total exposure (table <ref type="table" target="#tab_3">4</ref>).</s><s>Patients who received glucocorticoids had a higher incidence rate of SAEs, discontinuation due to AEs, SIEs and HZ versus patients who did not receive glucocorticoids (see online supplementary table <ref type="table" target="#tab_1">S2</ref>).</s><s>No differences in baseline demographics or efficacy were observed between the two subpopulations (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>To the best of our knowledge, this is the first study to analyse the efficacy and safety of an approved RA treatment in bDMARD-naive versus bDMARD-IR populations using pooled data from a large, randomised clinical trial programme.</s></p><p><s>Tofacitinib was effective in reducing the signs and symptoms of RA when used before or after bDMARDs.</s><s>In both bDMARD-naive and bDMARD-IR patients in the P2/P3 cohort, improvements in efficacy parameters at month 3 were significantly ( p&lt;0.05) greater for both tofacitinib doses versus placebo (except improvements ≥0.22 in HAQ-DI for bDMARD-IR patients who received tofacitinib 5 mg twice daily).</s><s>In general, improvements in clinical responses at months 3 and 6 were numerically greater for bDMARD-naive versus bDMARD-IR patients, with overlapping 95% CIs.</s><s>In particular, the proportions of patients achieving ACR20/50/70 responses were higher in the bDMARD-naive versus the bDMARD-IR subpopulation; the differences between the subpopulations for endpoints such as changes in DAS28-4(ESR), CDAI or SDAI, or achieving DA28-4(ESR), CDAI or SDAI remission or lowdisease activity were less prominent.</s><s>Of note, bDMARD-IR patients had longer disease duration and slightly greater disease activity at baseline compared with bDMARD-naive patients, which could have influenced these results.</s><s>Although no formal comparisons were made, numerically greater clinical responses were generally reported for tofacitinib 10 mg twice daily versus tofacitinib 5 mg twice daily; however, both tofacitinib doses reported significant improvements versus placebo across efficacy endpoints in both subpopulations.</s><s>Improvements in efficacy parameters were similar in bDMARD-IR tofacitinib-treated patients compared with TNFi-IR tofacitinib-treated patients from the ORAL Step study; this was expected given that these analyses included ORAL Step tofacitinib-treated patients (n=399). <ref type="bibr" target="#b33">27</ref></s><s>In bDMARD-IR subpopulations treated with tofacitinib, ACR and DAS response rates at months 3 and 6 were generally similar to those reported for non-TNFi bDMARDs, including abatacept, rituximab and tocilizumab in TNFi-IR patients, except DAS endpoints for tocilizumab 8 mg/kg. <ref type="bibr">10 13 14</ref></s><s>In bDMARD-naive patients treated with tofacitinib, clinical efficacy endpoints were generally similar to those reported for bDMARDs in patients who were bDMARD-naive or with early RA. <ref type="bibr">9 34-41</ref> More patients achieved efficacy endpoints at month 3 when treated with tofacitinib compared with placebo even after patients were stratified by exposure to previous TNFi.</s><s>While tofacitinib was significantly greater versus placebo in patients exposed to bDMARDs for many endpoints, patients with ≥2 previous TNFi exposure generally had poorer efficacy responses than bDMARD-naive patients and those with one previous TNFi exposure.</s><s>The number of patients in the multiple TNFi group was less than the other TNFi exposure groups; for several endpoints, responses were numerically higher but not statistically significant for tofacitinib versus placebo in the multiple TNFi group-possibly attributable to the smaller sample sizes for each treatment group, therefore, conclusions must be made with caution.</s><s>Baseline differences between the groups may impact on the differences in efficacy observed.</s><s>1]<ref type="bibr" target="#b14">[12]</ref><ref type="bibr" target="#b15">[13]</ref><ref type="bibr" target="#b16">[14]</ref><ref type="bibr" target="#b17">[15]</ref><ref type="bibr" target="#b18">[16]</ref><ref type="bibr" target="#b19">[17]</ref><ref type="bibr" target="#b20">[18]</ref><ref type="bibr" target="#b21">[19]</ref><ref type="bibr" target="#b22">[20]</ref><ref type="bibr" target="#b23">[21]</ref> Stratification by prior TNFi exposure also showed that ACR response rates in tofacitinibtreated bDMARD-IR patients were generally similar to non-TNFi bDMARDs, <ref type="bibr">10 13 14 19 20</ref> but greater than TNFi. <ref type="bibr">11 12 18-21</ref></s><s>The results of these analyses suggest that tofacitinib demonstrates efficacy compared with placebo in patients, irrespective of prior TNFi exposure; results were generally similar to those observed for bDMARDs.</s></p><p><s>In the P3 cohort, the tofacitinib safety profile appeared similar between treatment groups and between bDMARD-naive and bDMARD-IR subpopulations of patients with RA, with incidence rates that had overlapping 95% CIs.</s><s>Incidence rates for safety events were generally numerically higher for both tofacitinib doses versus placebo and tofacitinib 10 mg twice daily versus tofacitinib 5 mg twice daily for SIEs, HZ and malignancies (excluding NMSC), and in the bDMARD-IR versus bDMARD-naive subpopulations for discontinuations due to AEs, SAEs, HZ and malignancies (excluding NMSC).</s><s>Patients that received glucocorticoids had a higher incidence of SAEs, discontinuation due to AEs, SIEs and HZ (all serious HZ occurred in patients receiving glucocorticoids); consistent with reports from RA patient databases of bDMARDs. <ref type="bibr">42 43</ref></s><s>pportunistic infections (excluding TB), TB, malignancies, lymphoma/lymphoproliferative disorders and deaths were uncommon in both bDMARD-naive and bDMARD-IR tofacitinib-treated patients in the P3 cohort; higher rates were observed for tofacitinib 10 mg twice daily versus tofacitinib 5 mg twice daily, except deaths (overlapping 95% CIs).</s><s>There is no apparent or consistent association between tofacitinib dose and risk of malignancy. <ref type="bibr" target="#b50">44</ref></s><s>In phase III studies, nearly all TB cases occurred in regions of high TB endemicity. <ref type="bibr" target="#b51">45</ref></s><s>Similar to the bDMARD-IR subpopulation, these safety events were also uncommon in the tofacitinib ORAL Step study <ref type="bibr" target="#b33">27</ref> and studies of bDMARDs in TNFi-IR populations. <ref type="bibr">10 11 13 14</ref></s><s>Compared with tofacitinib-treated patients in the bDMARD-naive subpopulation, these safety events of special interest were generally similar to those reported for bDMARDs in patients who were Safety was assessed during months 0-6 for the placebo group and months 0-24 for the tofacitinib groups.</s><s>Patients who advanced from placebo to tofacitinib are counted in the placebo group until advancement in the various studies-some patients advanced at month 3, while others advanced at month 6 unless they did not achieve a 20% improvement in swollen/ tender joint counts at month 3, in which case they advanced to active treatment (ORAL Sync, ORAL Scan and ORAL Standard).</s><s>bDMARD, biological disease-modifying antirheumatic drug; IR, inadequate responders; MACE, major adverse cardiac events; N, number of patients included in analysis; NMSC, non-melanoma skin cancer; P3, phase III; SAE, serious adverse event.</s></p><p><s>bDMARD-naive or with early RA. <ref type="bibr">9 34-41 46</ref> The safety and efficacy profiles in bDMARD-naive and bDMARD-IR patients in the randomised controlled trials were generally similar to the data from tofacitinib LTE studies to date (data not shown <ref type="bibr" target="#b54">47</ref> ).</s><s>These pooled analyses provide a large data set for tofacitinib treatment groups in bDMARD-naive and bDMARD-IR subpopulations.</s><s>The limitations of the pooling of data from studies with different designs and methodology may result in a heterogeneous patient population (despite similar inclusion/exclusion criteria), making it difficult to detect changes due to larger variations in the analysed populations.</s><s>As patients were treated with placebo only for a short term, the placebo group had fewer patients and less exposure than the tofacitinib group in phase III studies, resulting in sample size differences for the comparisons at month 3.</s><s>The studies included in these analyses were not designed for comparisons between bDMARD-naive and bDMARD-IR patients and patients with/without concomitant glucocorticoids; patients were not randomised according to this stratification, no formal statistical analyses were performed to compare efficacy or safety between these subpopulations, and conclusions were based on descriptive analyses only.</s></p><p><s>In summary, tofacitinib was effective in reducing the signs and symptoms of RA when used before or after bDMARDs.</s><s>With a few exceptions, tofacitinib treatment resulted in greater efficacy responses in bDMARD-naive versus bDMARD-IR patients.</s><s>The tofacitinib safety profile appeared similar between subpopulations.</s><s>Taken together, these results suggest that tofacitinib provides an effective treatment option for both bDMARD-naive and bDMARD-IR patients.</s></p><p><s>Contributors KK, TH and EB were involved in conception and design of the study/ analyses.</s><s>KK performed data and statistical analyses.</s><s>CC-S, GB, PN, CAFZ, and RF were involved in data acquisition during the phase II, phase III and long-term extension clinical studies.</s><s>CC-S, GB, PN, CAFZ, KS, KK, TH, EB and RF were involved in data interpretation and manuscript drafting, reviewing and development.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 (</head><label>1</label><figDesc><div><p><s>Figure1(A) ACR20, (B) ACR50 and (C) ACR70 response rates (95% CI) at month 3 for bDMARD-naive versus bDMARD-IR populations in phase (P)2/ P3 cohort (FAS, NRI).</s><s>*p&lt;0.05;</s><s>**p&lt;0.001;</s><s>***p&lt;0.0001</s><s>vs placebo.</s><s>No preservation of type I error or multiple-comparisons correction was applied to p values as statistical significance defined as p&lt;0.05 was exploratory in nature; 95% CIs are exact binomial confidence intervals for single proportion.</s><s>ACR 20/50/70, proportion of patients achieving &gt;20%, &gt;50%, and &gt;70% improvement in American College of Rheumatology criteria; bDMARD, biologic disease-modifying antirheumatic drug; BID, twice daily; CI, confidence interval; FAS, full analysis set; IR, inadequate responders; NRI, non-responder imputation.</s></p></div></figDesc><graphic coords="4,220.65,48.42,332.62,525.94" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 LS mean change from baseline (95% CI) at month 3 in (A) HAQ-DI and (B) DAS28-4(ESR) for bDMARD-naive versus bDMARD-IR populations in the phase (P)2/P3 cohort (FAS, longitudinal model).</s><s>***p&lt;0.0001</s><s>vs placebo.</s><s>No preservation of type I error or multiple-comparisons correction was applied to p values as statistical significance defined as p&lt;0.05 was exploratory in nature; 95% CIs are based on normal approximation.</s><s>bDMARD, biologic disease-modifying antirheumatic drug; BID, twice daily; CI, confidence interval; DAS, disease activity score; ESR, erythrocyte sedimentation rate; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; IR, inadequate responders; LS, least squares.</s></p></div></figDesc><graphic coords="5,117.64,48.42,360.00,355.75" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patient demographics and baseline disease characteristics in the P2/P3 cohort The denominators were slightly less than the numbers of randomised patients (Ns), based on data collection and availability.</s><s>†% based on denominator of the total number of patients (per treatment) in the bDMARD-IR population, and these groups are mutually exclusive.</s><s>‡% based on denominator of the total number of patients (per treatment) who had previously taken TNFi in the bDMARD-IR population.</s><s>§% based on denominator of the total number of patients (per treatment) who had previously taken TNFi and other bDMARDs in the bDMARD-IR population.</s></p></div></figDesc><table><row><cell></cell><cell cols="2">bDMARD-naive</cell><cell></cell><cell>bDMARD-IR</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell><cell>Placebo</cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell></row><row><cell></cell><cell>Placebo</cell><cell>5 mg twice daily</cell><cell>10 mg twice daily</cell><cell></cell><cell>5 mg twice daily</cell><cell>10 mg twice daily</cell></row><row><cell></cell><cell>N=651</cell><cell>N=1071</cell><cell>N=1090</cell><cell>N=193</cell><cell>N=259</cell><cell>N=253</cell></row><row><cell>Caucasian, %</cell><cell>54.2</cell><cell>54.4</cell><cell>56.1</cell><cell>81.9</cell><cell>78.8</cell><cell>75.5</cell></row><row><cell>Female, %</cell><cell>82.8</cell><cell>85.0</cell><cell>85.0</cell><cell>81.9</cell><cell>84.2</cell><cell>83.0</cell></row><row><cell>Age in years, mean (SD)</cell><cell>52.0 (12.5)</cell><cell>52.6 (11.9)</cell><cell>52.3 (11.6)</cell><cell>54.0 (11.6)</cell><cell>54.7 (11.1)</cell><cell>54.9 (10.9)</cell></row><row><cell>Mean (SD) weight, kg</cell><cell>67.0 (17.7)</cell><cell>68.3 (17.9)</cell><cell>69.0 (18.0)</cell><cell>78.9 (23.0)</cell><cell>77.3 (22.3)</cell><cell>77.4 (22.1)</cell></row><row><cell>Geographic region, %</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>USA</cell><cell>12.0</cell><cell>11.4</cell><cell>12.9</cell><cell>44.0</cell><cell>44.8</cell><cell>47.8</cell></row><row><cell>Europe and Canada</cell><cell>34.4</cell><cell>35.5</cell><cell>35.3</cell><cell>38.3</cell><cell>32.0</cell><cell>30.0</cell></row><row><cell>Latin America</cell><cell>18.1</cell><cell>18.4</cell><cell>17.8</cell><cell>6.2</cell><cell>6.2</cell><cell>5.1</cell></row><row><cell>Rest of world</cell><cell>35.5</cell><cell>34.7</cell><cell>33.9</cell><cell>11.4</cell><cell>17.0</cell><cell>17.0</cell></row><row><cell>Mean (SD) disease duration, years</cell><cell>8.2 (8.2)</cell><cell>7.7 (7.4)</cell><cell>8.1 (7.9)</cell><cell>11.2 (8.6)</cell><cell>12.1 (9.1)</cell><cell>12.6 (8.6)</cell></row><row><cell>Mean (SD) BMI</cell><cell>25.6 (5.7)</cell><cell>26.2 (6.1)</cell><cell>26.5 (6.1)</cell><cell>29.3 (7.6)</cell><cell>29.0 (7.7)</cell><cell>28.8 (7.3)</cell></row><row><cell>% RF+</cell><cell>70.2</cell><cell>72.4</cell><cell>71.7</cell><cell>62.2</cell><cell>65.2</cell><cell>66.7</cell></row><row><cell>% anti-CCP+ (≥60 units)</cell><cell>69.0</cell><cell>67.2</cell><cell>65.6</cell><cell>62.7</cell><cell>63.2</cell><cell>65.3</cell></row><row><cell>Mean (SD) DAS28-4(ESR)*</cell><cell>6.3 (1.0)</cell><cell>6.4 (1.0)</cell><cell>6.4 (1.0)</cell><cell>6.4 (1.1)</cell><cell>6.5 (1.0)</cell><cell>6.5 (0.9)</cell></row><row><cell>Mean (SD)</cell><cell>1.3 (0.7)</cell><cell>1.4 (0.7)</cell><cell>1.4 (0.7)</cell><cell>1.6 (0.6)</cell><cell>1.6 (0.6)</cell><cell>1.5 (0.6)</cell></row><row><cell>HAQ-DI*</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD) SDAI*</cell><cell>38.0 (13.2)</cell><cell>38.9 (12.9)</cell><cell>38.6 (12.8)</cell><cell>39.9 (13.7)</cell><cell>40.7 (13.4)</cell><cell>39.8 (13.2 )</cell></row><row><cell>Mean (SD) CDAI*</cell><cell>36.2 (12.8)</cell><cell>37.0 (12.3)*</cell><cell>36.8 (12.5)</cell><cell>38.3 (13.3)</cell><cell>38.6 (12.5)</cell><cell>37.8 (12.3)</cell></row><row><cell>Mean (SD) tender joint count*</cell><cell>23.8 (13.9)</cell><cell>25.1 (14.7)</cell><cell>25.1 (14.9)</cell><cell>27.8 (16.9)</cell><cell>28.8 (16.7)</cell><cell>27.6 (15.8)</cell></row><row><cell>Mean (SD) swollen joint count*</cell><cell>15.2 (9.0)</cell><cell>15.1 (9.2)</cell><cell>15.0 (8.6)</cell><cell>16.8 (10.6)</cell><cell>16.1 (9.4)</cell><cell>16.5 (10.2)</cell></row><row><cell>Mean (SD) pain VAS*</cell><cell>56.1 (23.2)</cell><cell>58.6 (23.4)</cell><cell>59.1 (23.1)</cell><cell>60.1 (23.5)</cell><cell>64.3 (21.9)</cell><cell>61.4 (21.4)</cell></row><row><cell>Mean (SD) PtGA VAS*</cell><cell>56.3 (22.8)</cell><cell>59.5 (22.9)</cell><cell>59.0 (23.2)</cell><cell>61.2 (22.7)</cell><cell>64.4 (22.0)</cell><cell>61.5 (21.7)</cell></row><row><cell>Mean (SD) PGA VAS*</cell><cell>59.1 (17.0)</cell><cell>60.3 (16.8)</cell><cell>59.3 (16.8)</cell><cell>63.4 (16.6)</cell><cell>65.1 (17.4)</cell><cell>62.5 (18.6)</cell></row><row><cell>Mean (SD) CRP, mg/L*</cell><cell>13.5 (18.0)</cell><cell>16.2 (22.1)</cell><cell>15.5 (19.9)</cell><cell>15.7 (18.8)</cell><cell>19.6 (25.7)</cell><cell>18.8 (30.6)</cell></row><row><cell>Mean (SD) ESR, mm/h*</cell><cell>49.0 (25.0)</cell><cell>50.7 (26.6)</cell><cell>49.9 (26.1)</cell><cell>45.7 (24.0)</cell><cell>47.1 (26.0)</cell><cell>49.1 (27.6)</cell></row><row><cell>Previously taken methotrexate, %</cell><cell>89.6</cell><cell>90.4</cell><cell>90.9</cell><cell>96.4</cell><cell>95.0</cell><cell>90.9</cell></row><row><cell>Previously taken DMARDs other than methotrexate, %</cell><cell>61.8</cell><cell>61.1</cell><cell>61.7</cell><cell>33.2</cell><cell>49.8</cell><cell>47.8</cell></row><row><cell>Previously taken TNFi, %</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>95.9</cell><cell>94.2</cell><cell>97.2</cell></row><row><cell>Previously taken any other DMARDs, n (%)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>38 (19.7)</cell><cell>62 (23.9)</cell><cell>49 (19.4)</cell></row><row><cell>Abatacept</cell><cell></cell><cell></cell><cell></cell><cell>23</cell><cell>33</cell><cell>33</cell></row><row><cell>Anakinra</cell><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>6</cell><cell>3</cell></row><row><cell>Rituximab</cell><cell></cell><cell></cell><cell></cell><cell>7</cell><cell>1 6</cell><cell>1 1</cell></row><row><cell>Tocilizumab</cell><cell></cell><cell></cell><cell></cell><cell>7</cell><cell>1 4</cell><cell>1 2</cell></row><row><cell>Other</cell><cell></cell><cell></cell><cell></cell><cell>2</cell><cell>6</cell><cell>2</cell></row><row><cell>TNFi (no other bDMARD taken) †, n (%)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>155 (80.3)</cell><cell>197 (76.1)</cell><cell>204 (80.6)</cell></row><row><cell>One TNFi ‡</cell><cell></cell><cell></cell><cell></cell><cell>97 (62.6)</cell><cell>120 (60.9)</cell><cell>140 (68.6)</cell></row><row><cell>Multiple TNFi ‡</cell><cell></cell><cell></cell><cell></cell><cell>58 (37.4)</cell><cell>77 (39.1)</cell><cell>64 (31.4)</cell></row><row><cell>Other bDMARDs (no TNFi taken) †, n (%)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>8 (4.1)</cell><cell>15 (5.8)</cell><cell>7 (2.8)</cell></row><row><cell>TNFi and other bDMARDs †, n (%)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>30 (15.5)</cell><cell>47 (18.1)</cell><cell>42 (16.6)</cell></row><row><cell>One TNFi and</cell><cell></cell><cell></cell><cell></cell><cell>17 (56.7)</cell><cell>25 (53.2)</cell><cell>15 (35.7)</cell></row><row><cell>other bDMARD §</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Multiple TNFi and other bDMARDs §</cell><cell></cell><cell></cell><cell></cell><cell>13 (43.3)</cell><cell>22 (46.8)</cell><cell>27 (64.3)</cell></row></table><note><p><s>*bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; IR, inadequate responders; N, number of patients included in analysis; P2/P3, phase II/phase III; PGA, Physician Global Assessment of Arthritis; PtGA, Patient Global Assessment of Arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Efficacy responses at month 3 for bDMARD-naive versus bDMARD-IR in the P2/P3 cohort .0001</s><s>versus placebo.</s><s>No preservation of type I error or multiple-comparisons correction was applied to p values as statistical significance defined as p&lt;0.05 was exploratory in nature; 95% CIs are exact binomial CIs for single proportions.</s><s>†Low-disease activity.</s><s>‡Disease remission.</s><s>DAS28-4(ESR) and HAQ-DI data were FAS, NRI; CDAI and SDAI data were FAS, observed case; percentages were based on the number of patients available for each parameter analysis.</s><s>bDMARD, biological disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; DAS, disease activity score; ESR, erythrocyte sedimentation rate; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; IR, inadequate responders; N, number of patients with available ACR data at month 3; NRI, non-responder imputation; P2/P3, phase II/phase III; SDAI, Simplified Disease Activity Index.</s></p></div></figDesc><table><row><cell></cell><cell>bDMARD-naive</cell><cell></cell><cell></cell><cell>bDMARD-IR</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell><cell></cell><cell>Tofacitinib 5 mg</cell><cell>Tofacitinib</cell></row><row><cell>Parameter, %</cell><cell>Placebo</cell><cell>5 mg twice daily</cell><cell>10 mg twice daily</cell><cell>Placebo</cell><cell>twice daily</cell><cell>10 mg twice daily</cell></row><row><cell>(95% CI)</cell><cell>N=638</cell><cell>N=1043</cell><cell>N=1066</cell><cell>N=191</cell><cell>N=258</cell><cell>N=251</cell></row><row><cell>CDAI ≤10 †</cell><cell cols="2">14.3 (11.5 to 17.4) 32.4*** (29.5 to 35.4)</cell><cell>39.8*** (36.8 to 42.9)</cell><cell>14.4 (9.4 to 20.6)</cell><cell cols="2">29.5** (23.8 to 35.8) 35.9*** (29.7 to 42.5)</cell></row><row><cell>CDAI ≤2.8 ‡</cell><cell>0.7 (0.2 to 1.8)</cell><cell>6.4*** (5.0 to 8.2)</cell><cell>9.0*** (7.3 to 11.0)</cell><cell>1.2 (0.1 to 4.3)</cell><cell>5.9* (3.3 to 9.7)</cell><cell>6.5* (3.7 to 10.5)</cell></row><row><cell>SDAI ≤11 †</cell><cell cols="2">14.2 (11.4 to 17.3) 34.6*** (31.6 to 37.6)</cell><cell>41.1*** (38.0 to 44.2)</cell><cell>13.8 (8.9 to 19.9)</cell><cell cols="2">29.8*** (24.0 to 36.1) 38.3*** (32.0 to 44.9)</cell></row><row><cell>SDAI ≤3.3 ‡</cell><cell>0.7 (0.2 to 1.8)</cell><cell>6.4*** (4.9 to 8.1)</cell><cell>9.3*** (7.6 to 11.3)</cell><cell>0.6 (0.0 to 3.3)</cell><cell>6.8** (3.9 to 10.8)</cell><cell>8.3*** (5.0 to 12.6)</cell></row><row><cell>DAS28-4 (ESR)</cell><cell>4.5 (3.0 to 6.5)</cell><cell>16.6*** (14.3 to 19.2)</cell><cell>22.9*** (20.3 to 25.8)</cell><cell>5.1 (2.4 to 9.5)</cell><cell>12.7* (8.6 to 17.7)</cell><cell>17.8*** (13.0 to 23.4)</cell></row><row><cell>≤3.2 †</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>DAS28-4 (ESR)</cell><cell>2.3 (1.2 to 3.8)</cell><cell>7.3*** (5.7 to 9.2)</cell><cell>11.5*** (9.5 to 13.7)</cell><cell>2.3 (0.6 to 5.7)</cell><cell>6.6* (3.7 to 10.6)</cell><cell>8.4* (5.2 to 12.9)</cell></row><row><cell>&lt;2.6 ‡</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>HAQ-DI</cell><cell cols="2">28.7 (24.5 to 33.1) 52.9*** (49.5 to 56.3)</cell><cell>59.8*** (56.4 to 63.0)</cell><cell>36.9 (29.8 to 44.4)</cell><cell>45.7 (39.4 to 52.2)</cell><cell>55.3** (48.7 to 61.7)</cell></row><row><cell>improvement ≥0.22</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>HAQ-DI</cell><cell cols="2">18.2 (14.8 to 22.1) 40.3*** (37.0 to 43.6)</cell><cell>46.1*** (42.8 to 49.5)</cell><cell>20.1 (14.5 to 26.7)</cell><cell cols="2">31.0* (25.3 to 37.2) 39.2*** (33.0 to 45.8)</cell></row><row><cell>improvement ≥0.5</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">*p&lt;0.05; **p&lt;0.001; ***p&lt;0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Efficacy responses at month 6 for bDMARD-naive versus bDMARD-IR in the P2/P3 cohort (FAS, NRI)</s></p></div></figDesc><table><row><cell></cell><cell>bDMARD-naive</cell><cell></cell><cell>bDMARD-IR</cell><cell></cell></row><row><cell></cell><cell>Tofacitinib 5 mg twice daily</cell><cell>Tofacitinib 10 mg twice daily</cell><cell>Tofacitinib 5 mg twice daily</cell><cell>Tofacitinib 10 mg twice daily</cell></row><row><cell>Parameter, % (95% CI)</cell><cell>N=975</cell><cell>N=997</cell><cell>N=250</cell><cell>N=245</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Incidence rates (patients with event per 100 patient-years; 95% CI) for safety events of special interest in bDMARD-naive versus bDMARD-IR subpopulations in the P3 cohort</s></p></div></figDesc><table><row><cell></cell><cell>bDMARD-naive</cell><cell></cell><cell></cell><cell>bDMARD-IR</cell><cell></cell><cell></cell></row><row><cell>Safety event, incidence rate</cell><cell></cell><cell>Tofacitinib 5 mg</cell><cell>Tofacitinib 10 mg</cell><cell></cell><cell>Tofacitinib 5 mg</cell><cell>Tofacitinib 10 mg</cell></row><row><cell>(patients with event per 100</cell><cell>Placebo</cell><cell>twice daily</cell><cell>twice daily</cell><cell>Placebo</cell><cell>twice daily</cell><cell>twice daily</cell></row><row><cell>patient-years; 95% CI)</cell><cell>N=465</cell><cell>N=893</cell><cell>N=898</cell><cell>N=181</cell><cell>N=247</cell><cell>N=241</cell></row><row><cell>Exposure, patient-years</cell><cell>149.5</cell><cell>885.5</cell><cell>917.4</cell><cell>42.5</cell><cell>170.5</cell><cell>154.8</cell></row><row><cell>All SAEs</cell><cell>15.0 (9.9 to 22.7)</cell><cell>12.2 (10.0 to 14.8)</cell><cell>9.6 (7.8 to 11.9)</cell><cell>19.0 (9.5 to 38.0)</cell><cell>13.0 (8.5 to 20.0)</cell><cell>11.3 (7.0 to 18.1)</cell></row><row><cell>Discontinuations due to AEs</cell><cell>10.1 (6.1 to 16.7)</cell><cell>9.1 (7.3 to 11.3)</cell><cell>9.6 (7.8 to 11.9)</cell><cell>18.9 (9.5 to 37.8)</cell><cell>14.8 (10.0 to 21.9)</cell><cell>15.0 (10.0 to 22.5)</cell></row><row><cell>All serious infections</cell><cell>2.0 (0.6 to 6.2)</cell><cell>3.4 (2.4 to 4.9)</cell><cell>3.5 (2.5 to 4.9)</cell><cell>0</cell><cell>2.3 (0.9 to 6.3)</cell><cell>3.2 (1.3 to 7.8)</cell></row><row><cell>Herpes zoster (all-serious and</cell><cell>2.0 (0.7 to 6.3)</cell><cell>4.0 (2.8 to 5.5)</cell><cell>4.4 (3.2 to 6.0)</cell><cell>0</cell><cell>5.4 (2.8 to 10.4)</cell><cell>5.4 (2.7 to 10.7)</cell></row><row><cell>non-serious)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Herpes zoster (serious)</cell><cell>0</cell><cell>0.3 (0.1 to 1.1)</cell><cell>0.3 (0.1 to 1.0)</cell><cell>0</cell><cell>0.6 (0.1 to 4.2)</cell><cell>0</cell></row><row><cell>Herpes zoster (non-serious)</cell><cell>2.0 (0.7 to 6.3)</cell><cell>3.6 (2.5 to 5.1)</cell><cell>4.1 (3.0 to 5.7)</cell><cell>0</cell><cell>4.8 (2.4 to 9.6)</cell><cell>5.4 (2.7 to 10.7)</cell></row><row><cell>Tuberculosis</cell><cell>0</cell><cell>0</cell><cell>0.8 (0.4 to 1.6)</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Opportunistic infections</cell><cell>0</cell><cell>0.3 (0.1 to 1.1)</cell><cell>0.4 (0.2 to 1.2)</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>(excluding tuberculosis)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Malignancy (excluding NMSC)</cell><cell>0</cell><cell>0.6 (0.2 to 1.4)</cell><cell>0.9 (0.4 to 1.7)</cell><cell>0</cell><cell>1.2 (0.3 to 4.7)</cell><cell>1.9 (0.6 to 6.0)</cell></row><row><cell>Lymphoma/lymphoproliferative</cell><cell>0</cell><cell>0</cell><cell>0.1 (0.0 to 0.8)</cell><cell>0</cell><cell>0</cell><cell>0.6 (0.1 to 4.6)</cell></row><row><cell>disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>MACE</cell><cell>1.3 (0.3 to 5.4)</cell><cell>0.6 (0.2 to 1.4)</cell><cell>0.8 (0.4 to 1.6)</cell><cell>0</cell><cell>1.2 (0.3 to 4.7)</cell><cell>0.6 (0.1 to 4.6)</cell></row><row><cell>All cause mortality (30-day rule)*</cell><cell>0.7 (0.1 to 4.7)</cell><cell>0.6 (0.2 to 1.4)</cell><cell>0.4 (0.2 to 1.2)</cell><cell>0</cell><cell>1.2 (0.3 to 4.7)</cell><cell>0</cell></row></table><note><p><s>*30-day rule: deaths occurring within 30 days of the last dose.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2014-207178 on 14 August 2015. Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Charles-Schoeman C, et al. Ann Rheum Dis 2016;75:1293-1301. doi:10.1136/annrheumdis-2014-207178</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2014-207178 on 14 August 2015. Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Funding This study was sponsored by Pfizer.</s><s>Anne Marie Reid, PhD, of Complete Medical Communications provided editorial support under the guidance of the authors and was funded by Pfizer.</s><s>Lisy Wang, Ryan DeMasi and Andrew Anisfeld, all employees and shareholders of Pfizer, provided intellectual input during the manuscript development.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Competing interests CC-S, PN, CAFZ and RF have received research grants and consultancy fees from Pfizer.</s><s>GB is a member of the Speaker's Bureau for and has received research grants and consultancy fees from Pfizer.</s><s>KS, KK, TH and EB are employees and shareholders of Pfizer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient consent Obtained.</head><p><s>Ethics approval All studies were approved by the Institutional Review Boards (IRBs) and/or Independent Ethics Committees of each investigational centre or a central IRB.</s><s>The studies were conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice Guidelines.</s></p><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p><p><s>Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</s><s>See: http://creativecommons.org/ licenses/by-nc/4.0/</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Basic and translational research</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">No placebo patients are presented at month 6 as most patients advanced to active treatment at month 3; percentages were based on the number of patients available for each parameter analysis. *Low-disease activity. †Disease remission. ACR 20/50/70, proportion of patients achieving ≥20%, ≥50%, and ≥70% improvement in American College of Rheumatology criteria; bDMARD, biological disease-modifying antirheumatic drug; DAS, disease activity score; ESR, erythrocyte sedimentation rate; FAS, full analysis set</title>
		<imprint>
			<publisher>HAQ-DI</publisher>
		</imprint>
	</monogr>
	<note>Health Assessment Questionnaire-Disability Index; IR, inadequate responders</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">number of patients with available ACR data at month 6; month 6 analysis does not include phase II studies that were only 3 months in duration</title>
		<imprint>
			<biblScope unit="volume">NRI</biblScope>
			<biblScope unit="page" from="non" to="responder imputation" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m">P2/P3, Phase II/Phase III</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Verhoeven</surname></persName>
		</author>
		<idno type="DOI">10.1002/1529-0131(200001)43:1&lt;22::AID-ANR4&gt;3.0.CO;2-9</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="22" to="29" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Rheumatoid arthritis: principles of early treatment</title>
		<author>
			<persName><forename type="first">B</forename><surname>Bresnihan</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pubmed/12435163" />
	</analytic>
	<monogr>
		<title level="j">J Rheumatol Suppl</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="9" to="12" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Evidence supporting the benefit of early intervention in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pubmed/12435162" />
	</analytic>
	<monogr>
		<title level="j">J Rheumatol Suppl</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="3" to="8" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Pangan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Harrold</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.20452</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="856" to="864" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Rheumatoid Arthritis: early diagnosis and treatment outcomes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Heidari</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pubmed/24024009" />
	</analytic>
	<monogr>
		<title level="j">Caspian J Intern Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="161" to="170" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jamal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Patra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Keystone</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10067-008-1064-0</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="413" to="419" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/40.11.1211</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1211" to="1220" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pubmed/14969068" />
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="S154" to="157" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Simsek</surname></persName>
		</author>
		<idno type="DOI">10.2147/TCRM.S35784</idno>
	</analytic>
	<monogr>
		<title level="j">Ther Clin Risk Manag</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="403" to="408" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Keystone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Tony</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.092932</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1516" to="1523" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Doyle</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(09)60506-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="210" to="221" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Weinblatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Huizinga</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/kes150</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="2204" to="2214" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Greenwald</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.22025</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="2793" to="2806" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiff</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa050524</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="1114" to="1123" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Du Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gabay</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2011-200882</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="997" to="999" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Luggen</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2007.074773</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="547" to="554" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Gomez-Reino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Carmona</surname></persName>
		</author>
		<idno type="DOI">10.1186/ar1881</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">R29</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Decktor</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2011-150573</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1134" to="1142" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Malottki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tsourapas</surname></persName>
		</author>
		<idno type="DOI">10.3310/hta15140</idno>
	</analytic>
	<monogr>
		<title level="j">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1" to="278" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rendas-Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Wallenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Koncz</surname></persName>
		</author>
		<idno type="DOI">10.1186/ar3249</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">R25</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Matteson</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title/>
		<idno type="DOI">10.1136/annrheumdis-2013-203435</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1811" to="1818" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Genovese</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.33383</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="617" to="629" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Bloom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.24567</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1895" to="1905" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Wilkinson</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.33419</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="970" to="981" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nakamura</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.20494</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1150" to="1158" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase II study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takeuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamanaka</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.30512</idno>
	</analytic>
	<monogr>
		<title level="j">Mod Rheumatol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="514" to="521" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Charles-Schoeman</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-207178</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1293" to="1301" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-207178on14</idno>
		<imprint>
			<date type="published" when="2015-08">August 2015</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Charles-Schoeman</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(12)61424-X</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="page" from="451" to="460" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cush</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1109071</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="495" to="507" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hall</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-159-4-201308200-00006</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="253" to="261" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.37816</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="559" to="570" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Van Vollenhoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1112072</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="508" to="519" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Tofacitinib versus methotrexate in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hall</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1310476</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="2377" to="2386" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wollenhaupt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Silverfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="837" to="852" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sebba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.105197</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="88" to="96" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab&apos;s Efficacy in MTX iNadequate rEsponders (SERENE))</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deodhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Rigby</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2009.119933</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1629" to="1635" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors</title>
		<author>
			<persName><forename type="first">R</forename><surname>Westhovens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Robles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Ximenes</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.101121</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1870" to="1877" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bathon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Fleischmann</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM200011303432201</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="1586" to="1593" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Golimumab, a human anti-tumor necrosis factor and monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Moreland</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.24638</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="2272" to="2283" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Landewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mease</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.101659</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="797" to="804" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Weisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Kavanaugh</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.21519</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="26" to="37" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Klareskog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>De Jager</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(04)15640-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="675" to="681" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment</title>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gerhold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zink</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/kes305</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="53" to="61" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient</title>
		<author>
			<persName><forename type="first">A</forename><surname>Strangfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eveslage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schneider</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2011.151043</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1914" to="1920" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">V</forename><surname>Kaplan</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-205847</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="831" to="841" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Winthrop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gul</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-207319</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1133" to="1138" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">Meta-analysis of serious infections with tofacitinib and biological treatment in rheumatoid arthritis clinical trials</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ahadieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>French</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>abstract</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title/>
		<idno type="DOI">10.1002/art.38577</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page">S195</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wollenhaupt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Silverfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.130683</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="837" to="852" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Charles-Schoeman</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-2071781301</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1293" to="1301" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-207178on14</idno>
		<imprint>
			<date type="published" when="2015-08">August 2015</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
